At the time of the most recent check, Anixa Biosciences Inc. (Nasdaq: ANIX) shares were up 11.28% to $5.03 after the biotechnology company reported a clinical trial milestone.
What accomplishment has ANIX declared?
Anixa Biosciences (ANIX) said that the Phase 1a study of its prophylactic breast cancer vaccine has achieved the maximum tolerable dosage (MTD).
Anixa Biosciences is conducting a Phase 1a open-label, multiple ascending dosage trial to assess the safety and track the immune system’s response to immunization. Finding the highest tolerable dosage of the vaccination was a crucial objective. The maximum tolerated dosage (MTD) is the amount of medication or therapy that will have the desired effect without causing unfavorable side effects. Higher doses could work, but they might also have unwanted side effects that discourage usage or exceed the therapeutic advantages.
The breast cancer vaccine developed by ANIX, which is presently undergoing Phase 1 trials, makes use of endogenously generated proteins that serve a purpose at specific points in life before becoming “retired” and leaving the body. The vaccination also includes an adjuvant that prompts the body’s innate immune system to initiate an attack on newly forming tumors in an effort to stop their growth.
Dosing in subsequent Phase 2 and Phase 3 studies will be governed by the MTD. Based on the Phase 1a study’s current findings, a Phase 1b experiment just started. At Cleveland Clinic, ANIX is undertaking Phase 1a and Phase 1b studies with women who’ve already been diagnosed with triple-negative breast cancer, are now cancer-free and are at chance of recurrence, and healthy women who are at high risk of getting breast cancer later in life. Future trials are anticipated to take place across several locations.
How will ANIX continue to grow?
Anixa Biosciences (ANIX) will be finishing up registration for the Phase 1a study after reaching this significant milestone in the clinical development of its preventive breast cancer vaccine. ANIX will gather and evaluate the data and present the full immunological results from the study at a medical conference or comparable venue in the second quarter of 2023, following the vaccination of the final participant and the completion of all follow-up testing.